

Financial Results Briefing for the First Half of Fiscal Year Ending March 31,2024

November 15, 2023 (WED)



©2023 TOHO HOLDINGS CO., LTD. All rights reserved



Agenda

1 Financial Highlights for the First Half of Fiscal Year Ending March 31, 2024



- Forecast for Fiscal Year Ending March 31, 2024
- 3
- Medium-term Management Plan 2023-2025 "Create the Next Generation"



1 Financial Highlights for the First Half of Fiscal Year Ending March 31, 2024



Profit and Loss Statement (Consolidated)

(Unit: million Yen)

	1st half of FY ended N	March 2023	1st half of FY ending March 2024				
	Sum	% of net sales	Sum	% of net sales	YoY change (%)		
Net sales	681,470		734,846		7.83		
Gross profit	54,658	8.02	56,635	7.71	3.62		
SG&A	48,823	7.16	50,142	6.82	2.70		
Operating profit	5,835	0.86	6,492	0.88	11.26		
Ordinary profit	7,392	1.08	7,945	1.08	7.48		
Net profit*	3,598	0.53	8,782	1.20	144.08		

*Profit attributable to owners of parent



Balance Sheet (Consolidated)

(Unit: million Yen)

	FY ended Ma	rch 2023	1st half of	FY ending Ma	rch 2024	Major factors behind
	Sum	Proportion (%)	Sum	Proportion (%)	Incr. or decr.	the increase or decrease
Current assets	533,519	74.59	620,393	77.42	86,874	Increase in cash and deposits of 51,652 Increase in accounts receivable-trade of 38,349 Decrease in merchandise and finished goods of 2,975
Non-current assets	181,768	25.41	180,986	22.58	-782	Decrease in property, plant and equipment of 1,651
Total assets	715,288	100.00	801,379	100.00	86,091	
Current liabilities	440,188	61.54	502,754	62.74	62,566	Increase in accounts payable-trade of 80,543 Decrease in current portion of bonds payable of 20,003
Non-current liabilities	32,183	4.50	53,483	6.67	21,300	Increase in bonds payable of 22,103
Total liabilities	472,372	66.04	556,237	69.41	83,865	
Net assets	242,916	33.96	245,142	30.59	2,226	Increase in retained earnings of 7,734 Increase in treasury stock of 5,971(-)
Total liabilities and net assets	715,288	100.00	801,379	100.00	86,091	

Equity-to-asset ratio FY ended March 2023: 33.93% 1st half of FY ending March 2024: 30.56%



Profit and Loss Statement (Pharmaceutical Wholesaling Business)

- Growing sales of new drugs and specialty drugs, such as cancer drugs, and sales of therapeutic drugs expanded owing to the spread of the so-called ninth wave of COVID-19.
- The Company's net sales of limited-handling products for selected wholesalers were 98.8billion yen (21% increase from the previous period). *Excluding COVID-19 therapeutic agent
- Gross profit of customer support system 2 billion yen (5.5% increase from the previous period)

	1st half of FY ended	March 2023	1st half of FY ending March 2024				
	Sum	% of net sales	Sum	% of net sales	YoY change (%)		
Net sales	656,571		709,414		8.05		
Gross profit	37,140	5.66	38,955	5.49	4.89		
SG&A	32,057	4.88	32,143	4.53	0.27		
Operating profit	5,082	0.77	6,811	0.96	34.02		

Composition of Sales by Category and Contract Rate

Composition of sales by category

	April 2022-September 2022	April 2023-September 2023
Drugs for premium to promote the development of new drugs and eliminate off-label use	44.4%	51.0%
Patented drugs, others	27.0%	26.5%
Long-listed original drugs	16.8%	11.4%
Generic drugs	11.9%	11.2%

Contract rate

	2019/9	2020/3	2020/9	2021/3	2021/9	2022/3	2022/9	2022/3	2023/9
Value Basis	99.7%	99.7%	95.6%	100.0%	95.0%	100.0%	95.4%	98.6%	95.2%
Number Basis	100.0%	99.8%	80.6%	100.0%	71.1%	100.0%	69.6%	100.0%	69.3%



Profit and Loss Statement (Dispensing Pharmacy Business)

• We promoted responses to the revision of medical service fees and nine stores were closed or transferred with an emphasis on profitability. Three new stores opened.

• Increase in the number of prescriptions filled due to the recovery of the suppression of patient visits

(Unit: million Yen)

	1st half of FY ended I	March 2023	1st half of FY ending March 2024				
	Sum	% of net sales	Sum	% of net sales	YoY change (%)		
Net sales	45,089		46,598		3.35		
Gross profit	15,736	34.90	15,871	34.06	0.86		
SG&A	14,857	32.95	14,976	32.14	0.80		
Operating profit	878	1.95	895	1.92	1.94		

■ Number of stores (as of September 30, 2023)

	Consolidated Subsidiaries	Non-Consolidated Subsidiaries	Affiliates Companies	Total
TOHO HOLDINGS	4 companies 76 stores	8 companies 53 stores	2 companies 16 stores	14 companies 145 stores
PharmaCluster	6 companies 474 stores	10 companies 53 stores	2 companies 87 stores	18 companies 614 stores
Total	10 companies 550 stores	18 companies 106 stores	4 companies 103 stores	32 companies 759 stores





Forecast for Fiscal Year Ending March 31, 2024(Consolidated)

No change from initial announcement

1st half of FY ending March FY ending March 2024 (Forecasts) FY ended March 2023 2024 YoY change Forecast % of net Sum Sum **Progress (%)** % of net sales Incr. or Decr. Incr. or Decr. Sum sales (%) -4.82 Net sales 1,392,117 1,325,000 -67,117 734,846 55.46 114,366 8.22 113,400 8.56 -966 -0.84 56,635 **Gross profit** 49.94 98,000 7.04 3.98 50,142 SG&A 101,900 7.69 3,900 49.21 1.18 -4,865 16,365 0.87 -29.73 6,492 11,500 56.45 **Operating profit** 13,800 -5,376 **Ordinary profit** 19,176 1.38 1.04 -28.04 7,945 57.57 Net profit * 13,630 0.98 12,300 0.93 -1,330 -9.76 8,782 71.40

*Profit attributable to owners of parent

Forecast for Fiscal Year Ending March 2024 (Pharmaceutical Wholesaling Business)



	FY ended Mar	ch 2023	FY en	ding March 20	2024 (Forecasts)			1st half of FY ending Marc 2024	
			Forecas	st	ҮоҮ с	hange			
	Sum	% of net sales	Sum	% of net sales	Incr. or Decr.	Incr. or Decr. (%)		Sum	Progress (%)
Net sales	1,340,318		1,273,000		-67,318	-5.02		709,414	55.73
Gross profit	78,463	5.85	77,500	6.09	-963	-1.23		38,955	50.26
SG&A	64,468	4.81	65,500	5.15	1,032	1.60		32,143	49.07
Operating profit	13,995	1.04	12,000	0.94	-1,995	-14.26		6,811	56.76

×

Forecast for Fiscal Year Ending March 2024 (Dispensing Pharmacy Business)

	FY ended Mar	ch 2023	FY en	FY ending March 202			1st half of FY ending March 2024	
			Forecas	st	ҮоҮ с	hange		
	Sum	% of net sales	Sum	% of net sales	Incr. or Decr.	Incr. or Decr. (%)	Sum	Progress (%)
Net sales	92,346		92,400		54	0.06	46,598	50.43
Gross profit	32,160	34.83	32,100	34.74	-60	-0.19	15,871	49.44
SG&A	29,728	32.19	30,200	32.68	472	1.59	14,976	49.59
Operating profit	2,431	2.63	1,900	2.06	-531	-21.84	895	47.11



Dividend Outlook

	Interim	Year End	Annual Dividend
FY ended March 2022	15yen	15yen	30yen
FY ended March 2023	16yen	16yen	32yen
FY ending March 2024 (Forecasts)	18yen (Ordinary dividend: 16yen Commemorative dividend: 2yen)	18yen (Ordinary dividend: 16yen Commemorative dividend: 2yen)	36yen (Ordinary dividend: 32yen Commemorative dividend: 4yen)

(*) We plan to pay an interim dividend of 18 yen per share and a year-end dividend of 18 yen per share for Fiscal year ending March 2024, with an annual dividend per share totaling 36 yen. Each of the interim and year-end dividends will be comprised of an ordinary dividend of 16 yen and a special dividend of 2 yen commemorating the 75th anniversary of the company's foundation.





Medium-term Management Plan 2023-2025 "Create the Next Generation"

©2023 TOHO HOLDINGS CO., LTD. All rights reserved

Basic policy and specific measures of the Medium-term Management Plan 2023-2025 "Create the Next Generation"



Business transformation

- Transformation of Pharmaceutical wholesaling business
- Transformation of Dispensing pharmacy business
- Regional development Regional healthcare design
- Cooperative Research Lab with AIST, MAXIS2021

Investment for growth and improvement of profitability

- Specialty products, Full service
- Improvement of customer support business
- Building new businesses

Alliance Further expansion of DX


Improvement of Capital Efficiency and Enhancement of Shareholder Returns

- · What the "next generation" should be like
- Specific measures under the Medium-term Management Plan 2023-2025 " Create the Next Generation"

Sustainability management

- Sustainability management of our company
- Maximize the value of human capital
- Compliance/ Risk management

Transformation of Pharmaceutical wholesaling business



Transformation of Dispensing pharmacy business



Restructuring dispensing pharmacy subsidiaries

During the period of the current Medium-Term Management Plan, we will proceed with the integration and restructuring of the 27 dispensing pharmacy companies nationwide toward better functioning through concentration of management functions and system integration.

 \checkmark Consolidated two companies on October 1

Opened new pharmacies while closing existing ones with an emphasis on profitability

 \checkmark In the first half of the fiscal year under review, we opened three stores and closed and transferred nine stores.

Business site integration associated with the Daizawa Project

 \checkmark PFP Daizawa, base for sales of pharmaceuticals in small lots, integrated into PFP Saitama

Promotion of DX

Improving pharmacy operational efficiency and patient convenience through active promotion of DX. ✓ Development a portal application, Kyoso Mirai Pharmacy Health Navi, which includes a function for sending prescriptions and an electronic medicine notebook




Promotion of DX for pharmacy operations





Helping patients at all stages, from finding hospitals and pharmacies to receiving and following up on medications



Joint research with the National Institute of Advanced Industrial Science and Technology (AIST) -Aim to realize of Universal Medical Access-





8 researchers on loan from the Group and 16 in-house researchers

Collaborative Research Lab established to conduct joint research on four themes

Development of new transport technologies for regenerative medicine products

Development of technology needed for telemedicine

Sophistication of distribution bases

Data collection and utilization technologies

Toward building "Specialty products, Full service"



(Market derivation)


- Diversification of modalities(Diversification of needs)
- Expansion of specialty products

(Required Features)

- BCP · Optimization of distribution inventory
- Temperature control Sales/Support Management by patient


Initiatives in the First Half

- Compilation of "Proposal for Business Continuity Plan in the Supply of Pharmaceuticals"
- Joint Disaster Prevention Drill with the Ground Self-Defense Force



Contribution to the establishment of a system to provide safe and secure medical care to patients in need of treatment.

Improvement of customer support business



Changes in the performance of Customer Support System(Gross profit)

Improvement of existing customer support business

- Development of cloud version of LXMATE HeLios ٠
- Promotion of switching from ENIF (free) to FutureENIF (paid)
- Taking on the challenge of new business by utilizing the voice-recognition technology cultivated by the development of the ENIFvoice series.

Development of new customer support business through alliances and internal projects


MICIN AIST MAXIS



Efforts to growth areas and new businesses



Evolution of customer support business through alliances



Efforts to Global Markets and EC Markets

 \Rightarrow Entry into the e-commerce business in China, which has potential for growth.

Capital and business tie-up with biotech venture companies

⇒Supporting the development of specialty products such as biomedical products and regenerative medical products and collaborating in their distribution.

Sustainability management


Environment Social Governance

We work to solve social issues through our business and contribute to the realization of a sustainable society.

Efforts to decarbonization



Setting CO2 emission reduction targets



Paperless promotion

Promotion of a 80% reduction in Headquarters-related paper due to the relocation of Head Office functions

Stable supply • BCP

With the participation of pharmaceutical companies, etc., the "the Study Group for Establishment of BCP System" was established to comply a Proposal for Business Continuity Plan in the Supply of Pharmaceuticals in the event of a disaster.

→ We have been compiled as a "Proposal for Business Continuity Plan in the Supply of Pharmaceuticals," and will prepare to submit this Proposal to public authorities and local governments.

Human capital · Health management

Human resources/Training

Enhancement of training(Management training by external instructors, Reskilling) **Development of the personnel system**

Expansion of mid-career employment, Appointment of contract employees as full-time employees

Work-style reforms

Increase in the amount of average periodic wage increase, Review of vacation days (full fiveday work week/ Increase in the number of summer vacation days) and

Introduction of office casual throughout the year

Work-style reforms

Strengthen promotion system and conduct training for employees

Compliance

All employees receive Group Compliance Training every month

Improvement of Capital Efficiency and Enhancement of Shareholder Returns



Specific measures under the Medium-term Management Plan 2023-2025 "Create the Next Generation"

1) Investment Plan	38 billion yen	3) Dividends	We will increase dividends stably with a target of a DOE (dividend on equity) of 2%.
2) Purchase of treasury shares	More than 30 billion yen	4) Cross-shareholdings	We will unwind cross-shareholdings in a phased manner through sufficient dialogue with the partner companies.

Major Results for the First Half

Purchase of treasury shares

Acquired treasury shares to improve shareholder return and capital efficiency.

- May 31: 6.0billion yen *Ended June 1
- September 15: 6.0billion yen (Maximum) *Until March 31, 2024
 (as of October 31: Total number of shares acquired: 389,100 shares/Total cost of stock acquired: 1,262,246,600 yen)

 Cancellation of all shares of treasury stock acquired as described above (Planned cancellation date: March 31, 2024)

Cross-shareholdings

Sale of investment securities to improve the asset efficiency and strengthen the financial structure of the Company. Amount sold: 7 billion yen



References

©2023 TOHO HOLDINGS CO., LTD. All rights reserved




	1st half of FY ended March 2023	1st half of FY ending March 2024	Major factors for 1st half of FY ending March 2024
Cash and cash equivalents at the beginning of period	90,014	81,839	
Operating activities	10,693	53,933	Profit before income taxes: 13,029 Depreciation: 3,098 Increase in trade payables: -36,996 Decrease in inventories: 3,237 Increase in trade payables: 79,022 Income taxes paid: -4,765
Investment activities	-407	3,515	Purchase of property, plant and equipment: -966 Purchase of intangible assets: -792 Purchase of investment securities: -1,955 Proceeds from sale of investment securities: 6,977
Financing activities	-2,960	-5,775	Repayments of long-term borrowings: -1,335 Issuance of bonds: 22,110 Redemption of bonds: -20,000 Purchase of treasury shares: -6,001
Cash and cash equivalents at the end of period	97,855	133,516	Increase(1st half of FY ending March 2024): 51,676

SG&A (Year on Year)

<Year on Year>





+0.29 billion yen

+0.19 billion yen

+0.18 billion yen

+0.07 billion yen

+0.05 billion yen

+0.15 billion yen

Capital Investment and Depreciation



[Capital Investment]

1st half of FY ended March 2023	1st half of FY ending March 2024	FY ending March 2024
Results: 946 million yen	Results:1,647 million yen	Forecasts: 6,791 million yen
 "TBC Hokuriku" (system, fixtures) 208 million yen Pharmaceutical sales office (New construction, relocation of sales office and others) : 320 million yen Others : 418 million yen Including, replacement of core system servers : 99 million yen Replacement of WMS terminal units, etc. 28 million yen 	 Pharmaceutical sales office (New construction, relocation of sales office and others) : 589 million yen Replacement of core system servers : 459 million yen Others : 599 million yen Including, system development, etc. : 190 million yen Replacing an IP Phone, etc. : 156 million yen 	 Relocated to Tokyo Midtown Yaesu Move-in construction work · System · Furniture, fixtures, etc. : 970 million yen Pharmaceutical sales office (New construction, relocation of sales office and others) : 2,506 million yen Others : 3,315 million yen Including, replacement of core system servers : 474 million yen Distribution center WMS (warehouse management system) renovation, introduction of cloud-based systems, etc. : 923 million yen
[Depreciation]		

1st half of FY ended March 2023	1st half of FY ending March 2024	FY ending March 2024
2,746 million yen	2,934 million yen	6,139 million yen

Major customer support systems results



ENIFvoice SP, ENIFvoice SP+A, ENIFvoice Core



Support for improving efficiency in medication counseling and the preparation of the medication history of a patient as well as up skilling at pharmacies by introducing voice input systems. In addition, ENIFvoice SP+A/ ENIFvoice Core, upgraded versions of ENIFvoice SP, enable inter-terminal and inter-store data sharing via a cloud server.

Number of sales: **16,800** units

Initial examination reservation service

	TRAC.	9614	n) A	110182	101	7
ROUND.	NUTERNA .					
	211442.24					
			2014918			
			1	2		
			-	-	-	-
5					10	- 10
-	-	-	0	0	0	0
10	10	- 10	43	10	10	-
-	0	0	0	0	0	0
10	20	21	32	20	28	- 25

Launched in 2012

Constructed an Internet environment where a new patient can easily book the first medical examination via a medical institution's website or medical institutions search site. It also enables a patient to reserve a reexamination and/or a thorough medical checkup.

Number of account registration: 13,451 hospitals/clinics

Centralized administration system of pharmacy operation

Mizar



This system realizes the centralized management of sales, inventories and accounts receivable for all pharmacy stores at the headquarters. With automatic order placement based on prescription data, it contributes to significantly reduce pharmacists' time and efforts needed for ordering.

> Number of sales (** on a contract basis): 3,228 stores

Information terminal for pharmaceutical ordering **ENIF**



This system makes pharmaceutical ordering operations dramatically more efficient. Any user can easily place an order simply by scanning the relevant barcode through the terminal, which eliminates the need for cumbersome ordering operations via the telephone.

Number of units introduced: **27,021** units

as of October 2023